Innovative Medicine
healthcare areas

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Immunology/
      3. Autoantibody diseases/
      4. Maternal Fetal Alloimmune diseases of pregnancy

      Maternal Fetal Alloimmune diseases of pregnancy

      Johnson & Johnson aims to help address the unmet needs persisting for families impacted by alloimmune diseases of pregnancy, including Fetal and neonatal alloimmune thrombocytopenia (FNAIT) and Hemolytic disease of the fetus and newborn (HDFN), by pioneering an innovative approach that may change the course of treatment for these conditions in the future.
      Disease areas
      Maternal Fetal Alloimmune diseases of pregnancy
      Hemolytic disease of the fetus and newborn (HDFN)
      June 18, 2025
      Maternal Fetal Alloimmune diseases of pregnancy
      Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
      June 18, 2025
      JJ_Photo_LatinaFacility_3238.png
      Newsroom
      See latest maternal-fetal immunology news by visiting our newsroom.
      Learn more
      Featured resources
      In the news
      Experts share insights on potential new treatment for HDFN
      Our people
      Three career learnings about clinical research in maternal-fetal health
      In the news
      How Johnson & Johnson is breaking the blood barrier and making strides to better understand HDFN
      In the news
      Johnson & Johnson readies ‘pipeline in a product’ for pivotal year
      Patient stories
      “I had a condition that threatened my chances of having healthy children”
      What to know about HDFN, a serious blood disorder in babies, including a possible new treatment